Latest news articles

Added 5 months ago Drug news

FDA approves Inrebic to treat primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis

Celgene Corporation announced the FDA has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary...

Added 10 months ago Drug news

FDA accepts NDA for fedratinib to treat myelofibrosis

Celgene Corporation announced the FDA has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority Review....

Added 11 months ago Drug news

CTI BioPharma Corp. will withdraw its application (MAA) to EMA for pacritinib as a treatment for myelofibrosis.

CTI BioPharma Corp. announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment...

Search all news articles for Other haematologic conditions

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more


Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...

Added 4 years ago

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012), but since then Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for use in the European Union and highly prevalent mutations in the Calreticulin gene (CALR)...

Added 5 years ago

Guideline for the diagnosis and management of myelofibrosis

The purpose of this guideline is to provide a practical, rather than a research, approach to the diagnosis, investigation and management of patients with primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and...

Added 7 years ago

Search all guidelines for Other haematologic conditions

Journal articles

Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth

Postpartum hemorrhage is the most common cause of maternal death. Oxytocin is the standard therapy for the prevention of postpartum hemorrhage , but it requires cold storage, which is not available in many countries.

Added 1 year ago

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.

Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies.

Added 2 years ago

Erythrocytosis following testosterone therapy.

A rapid increase in awareness of androgen deficiency has led to substantial increases in prescribing of testosterone therapy (TTh), with benefits of improvements in mood, libido, bone density, muscle mass, body composition, energy, and cognition.

Added 2 years ago

Search all journal articles for Other haematologic conditions

Clinical trials

Carbetocin RTS for preventing postpartum haemorrhage: a randomized non-inferiority controlled trial (CHAMPION)

A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using carbetocin room temperature stable (RTS) for the prevention of postpartum...

Added 1 year ago

Search all clinical trials for Other haematologic conditions